Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across ...

At four-years-old, William Moore’s muscles are already beginning to deteriorate. Something as small as a slight gust of wind and sometimes even just thin air is enough to knock William over. Diagnosed ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%.” - The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, January ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which included a patient death from November in a patient who ...

The recent data from Sarepta’s Elevidys Phase III trial demonstrated significant improvements in primary and functional endpoints, which establishes the treatment’s efficacy and safety.

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...